Do you lose more weight on 5mg Mounjaro than on 2.5mg?

What SURMOUNT-1 tells us about 2.5mg versus higher doses

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across three dose arms: 5mg, 10mg and 15mg tirzepatide, each compared with placebo. A 2.5mg starting phase came first for all participants, but 2.5mg was never a stand-alone treatment arm, the trial was built around the principle that it is a run-in dose, not a maintenance one.

The results showed a clear dose-response pattern. At 72 weeks, participants on 5mg lost an average of around 15% of their body weight. Those on 10mg lost roughly 19.5%, and those on 15mg around 20.9%. So 5mg does produce real weight loss (considerably more than placebo) but it sits at the lower end of what tirzepatide can achieve. If you are asking whether you will lose more weight on 5mg Mounjaro compared with the starter dose, the answer is yes for most people, though the full picture is more nuanced than a simple comparison suggests. Framing 5mg as simply "better than 2.5mg" understates the picture; 5mg is the first therapeutic dose, where the medicine starts doing the job it is licensed to do.

NICE drew on this data when it recommended tirzepatide in Technology Appraisal TA1026, noting that the evidence supports titrating to the highest tolerated dose for maximum benefit, and recommending that continuing treatment should be reviewed if weight loss is below 5% after six months at the highest tolerated dose. That framing matters: "highest tolerated" is the goal, and 5mg may be the right stopping point for some people while others move further.

Why 2.5mg produces less weight loss, the mechanism

Tirzepatide works by activating both GIP and GLP-1 receptors, slowing gastric emptying, reducing appetite signals, and improving how the body handles blood sugar. At 2.5mg, those effects are present but modest. The dose is calibrated to give the gut time to adapt, which is why nausea and other gastrointestinal effects are generally milder in the first four weeks. Appetite suppression is real but limited at this level.

As the dose increases, receptor engagement strengthens. The appetite-reducing signal becomes more pronounced, gastric emptying slows further, and calorie intake tends to fall more consistently. That is the biological basis for the dose-response curve seen in the trial. It is also why switching from 2.5mg to 5mg after four weeks is a standard clinical step rather than an optional one for most people: staying at 2.5mg long-term would mean accepting a fraction of the medicine's potential effect. If you want a fuller picture of what happens as doses climb beyond 5mg, the evidence on higher Mounjaro doses covers 7.5mg through to 15mg in detail.

What 5mg weight loss looks like in practice

Around 15% average weight loss over 72 weeks is a meaningful clinical result. For someone starting at 100 kg, that is roughly 15 kg. But "average" carries a wide distribution: some people on 5mg lose considerably more, others less, depending on diet, activity, adherence and individual biology. The page on whether you lose more weight on 5mg Mounjaro explores this variation in detail, including what the trial data shows about the range of outcomes at this dose. The NHS guidance on tirzepatide, available on the NHS medicines page for tirzepatide, notes that weight loss varies between people and that the medicine should be used alongside a reduced-calorie diet and increased physical activity.

One practical point worth knowing: dose titration follows a four-week schedule, so moving from 2.5mg to 5mg happens roughly a month after starting. Some people begin treatment mid-month, after payday or at the start of a new week, which means their four-week review lands at an awkward time; your prescriber's timeline is what counts, not the calendar. Never adjust your own dose or extend a dose phase, that is a clinical decision, confirmed at each review.

For a sharper focus on whether 5mg specifically is producing the results you might expect, the page on weight loss at 2.5mg gives useful context on what that starter dose can and cannot achieve. And if you are weighing up what a private prescription actually costs at each dose, the Mounjaro cost page sets out the market picture honestly.

How a prescriber decides which dose is right for you

No prescriber assigns a dose based on trial averages alone. The clinical assessment looks at how you responded to the previous dose: how much weight you've lost, whether side effects are manageable, and whether there are any clinical reasons to pause or slow titration. A small number of people do stay at 5mg long-term because 10mg is not tolerable for them; for most, the aim is to reach the highest dose the body accepts.

These are prescription-only medicines. Every repeat order with a regulated service involves a clinical re-review, not just a box-ticking renewal. At nume, a GPhC-registered prescriber reads your update before any repeat is issued. If you are curious whether this treatment is right for you or want to understand where you'd sit in the titration schedule, checking your eligibility starts that conversation at no cost. The full Mounjaro guide covers everything from how the medicine works to what to expect across the treatment schedule.